Contraception · Adverse Effects

Progestin-only contraceptives: effects on weight

Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, Helmerhorst FM

Published August 28, 2016 The Cochrane Database of Systematic Reviews, 2016(8), CD008815
DOI 10.1002/14651858.CD008815.pub4 PMID 27567593 PMC PMC5034734

RRM Academy Synopsis

Progestin-only contraceptives show limited evidence of weight gain

Progestin-only contraceptives showed limited evidence of weight gain in 22 studies, according to a Cochrane systematic review of 11,450 women. Most studies found mean gains of less than 2 kg (4.4 lb) by 6 or 12 months. In 15 studies, users and comparison groups showed no significant difference in weight or other body measures.

Key Findings

  • In most studies mean gain was below 2 kg (4.4 lb) at 6 or 12 months; in multiyear data, mean change at two to four years was approximately twice the one-year change.
  • 15 studies found no significant difference in weight or other body composition measures; 5 with moderate or low quality evidence found differences, and 2 six-rod implant studies found some (low quality).
  • Three studies of depot medroxyprogesterone acetate (DMPA) reported differences from no hormonal method (low quality evidence): greater weight gain in two retrospective studies, and more body fat in one study of adolescents.
  • DMPA exceeded copper intrauterine contraception in mean weight gain by 2.28 kg (95% CI 1.79 to 2.77), 2.71 (2.12 to 3.30) and 3.17 (2.51 to 3.83) at one, two and three years.
  • Perimenopausal users of levonorgestrel-releasing intrauterine contraception (MD 1.60, 95% CI 0.45 to 2.75) or a desogestrel pill (MD 3.30, 2.08 to 4.52) had greater fat mass (%) increases than the control group.

Interpretation

The authors analyzed 5 randomized controlled trials and 17 non-randomized studies separately, since methods and weight reporting differed too much to pool. They rated the overall evidence low quality: 12 of the 22 studies low, three moderate and seven very low. Main reasons were lack of randomization and high loss to follow-up. Of the five studies reporting differences, two were retrospective chart reviews and three were prospective without random assignment. The findings describe associations. In one retrospective study, the weight gain difference with DMPA was not notable in the obese subgroup. Studies with multiyear data generally showed no significant group differences.

RRM Context

RRM Academy uses the term suppressive medications for hormonal birth control, including the progestin-only methods in this review. RRM clinicians look for the cause of a cycle symptom before prescribing. The review left out studies where a progestin treated a medical condition, so its weight findings describe use for contraception.

Abstract

Background

Progestin-only contraceptives (POCs) are appropriate for many women who cannot or should not take estrogen. POCs include injectables, intrauterine contraception, implants, and oral contraceptives. Many POCs are long-acting, cost-effective methods of preventing pregnancy. However, concern about weight gain can deter the initiation of contraceptives and cause early discontinuation among users.

Objectives

The primary objective was to evaluate the association between progestin-only contraceptive use and changes in body weight.

Search Methods

Until 4 August 2016, we searched MEDLINE, CENTRAL, POPLINE, LILACS, ClinicalTrials.gov, and ICTRP. For the initial review, we contacted investigators to identify other trials.

Selection Criteria

We considered comparative studies that examined a POC versus another contraceptive method or no contraceptive. The primary outcome was mean change in body weight or mean change in body composition. We also considered the dichotomous outcome of loss or gain of a specified amount of weight.

Data Collection and Analysis

Two authors extracted the data. Non-randomized studies (NRS) need to control for confounding factors. We used adjusted measures for the primary effects in NRS or the results of matched analysis from paired samples. If the report did not provide adjusted measures for the primary analysis, we used unadjusted outcomes. For RCTs and NRS without adjusted measures, we computed the mean difference (MD) with 95% confidence interval (CI) for continuous variables. For dichotomous outcomes, we calculated the Mantel-Haenszel odds ratio (OR) with 95% CI.

Main Results

We found 22 eligible studies that included a total of 11,450 women. With 6 NRS added to this update, the review includes 17 NRS and 5 RCTs. By contraceptive method, the review has 16 studies of depot medroxyprogesterone acetate (DMPA), 4 of levonorgestrel-releasing intrauterine contraception (LNG-IUC), 5 for implants, and 2 for progestin-only pills.Comparison groups did not differ significantly for weight change or other body composition measure in 15 studies. Five studies with moderate or low quality evidence showed differences between study arms. Two studies of a six-rod implant also indicated some differences, but the evidence was low quality.Three studies showed differences for DMPA users compared with women not using a hormonal method. In a retrospective study, weight gain (kg) was greater for DMPA versus copper (Cu) IUC in years one (MD 2.28, 95% CI 1.79 to 2.77), two (MD 2.71, 95% CI 2.12 to 3.30), and three (MD 3.17, 95% CI 2.51 to 3.83). A prospective study showed adolescents using DMPA had a greater increase in body fat (%) compared with a group not using a hormonal method (MD 11.00, 95% CI 2.64 to 19.36). The DMPA group also had a greater decrease in lean body mass (%) (MD -4.00, 95% CI -6.93 to -1.07). A more recent retrospective study reported greater mean increases with use of DMPA versus Cu IUC for weight (kg) at years 1 (1.3 vs 0.2), 4 (3.5 vs 1.9), and 10 (6.6 vs 4.9).Two studies reported a greater mean increase in body fat mass (%) for POC users versus women not using a hormonal method. The method was LNG-IUC in two studies (reported means 2.5 versus -1.3; P = 0.029); (MD 1.60, 95% CI 0.45 to 2.75). One also studied a desogestrel-containing pill (MD 3.30, 95% CI 2.08 to 4.52). Both studies showed a greater decrease in lean body mass among POC users.

Authors' Conclusions

We considered the overall quality of evidence to be low; more than half of the studies had low quality evidence. The main reasons for downgrading were lack of randomizations (NRS) and high loss to follow-up or early discontinuation.These 22 studies showed limited evidence of change in weight or body composition with use of POCs. Mean weight gain at 6 or 12 months was less than 2 kg (4.4 lb) for most studies. Those with multiyear data showed mean weight change was approximately twice as much at two to four years than at one year, but generally the study groups did not differ significantly. Appropriate counseling about typical weight gain may help reduce discontinuation of contraceptives due to perceptions of weight gain.

Topics

By this author

Related research

Contraception › Adverse Effects › Cardiovascular Effects · Therapeutics › Hormonal Agents › Progesterone and Progestins
Laureen M Lopez, Shanthi Ramesh, Mario Chen, Alison Edelman, Conrad Otterness, James Trussell, Frans M Helmerhorst
L Lopez, S Ramesh, M Chen, A Edelman, C Otterness, Jim Trussell, Jimmy Trussell, J Trussell, F Helmerhorst
PMID 27567593 27567593 DOI 10.1002/14651858.CD008815.pub4 10.1002/14651858.CD008815.pub4 Lopez et al. 2016, Lopez 2016